Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Philip Kuo, MD, PhD, University of Arizona Cancer Center

Videos

Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Philip Kuo , MD, PhD;

Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...

Philip Kuo, MD, PhD, shares...

11/10/2023

Oncology

Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre

Videos

Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer

11/02/2023

Shahneen Sandhu , MBBS;

In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.

In a prospective observational...

11/02/2023

Oncology

Elena Castro, MD, PhD Hospital Universitario 12 de Octubre

Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations

11/01/2023

Elena Castro , MD, PhD;

Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.

Elena Castro, MD, shares final...

11/01/2023

Oncology

Henrik Grönberg, MD, PhD, Karolinska Institute

Videos

Comparing Androgen Receptor Pathway Inhibitors and Taxanes for Metastatic Castration-Resistant Prostate Cancer in a Biomarker-Driven, Outcome-Adaptive Platform Trial

10/26/2023

Henrik Grönberg , MD, PhD;

Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...

Henrik Grönberg, MD, PhD, shared...

10/26/2023

Oncology

Videos

177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

10/25/2023

Oliver Sartor , MD;

At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.

At the 2023 ESMO Congress,...

10/25/2023

Oncology

Videos

Identifying Biomarkers to Predict Resistance to Lutetium-177–PSMA-617

10/11/2023

Oliver Sartor , MD;

At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.

At the 2023 EANM meeting, Oliver...

10/11/2023

Oncology

Gerard Morton, MD, Odette Cancer Center at Sunnybrook Research Institute

Videos

Methods of Radiation Dose Intensification for High-Risk Prostate Cancer

03/21/2023

At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.

At the 2023 ACRO Radiation...

03/21/2023

Oncology

Videos

No Improvement to Survival Outcomes With Pembrolizumab Plus Docetaxel for Castration-Resistant Prostate Cancer

03/10/2023

Daniel Petrylak, MD, discusses an abstract presented at 2023 ASCO Genitourinary Cancers Symposium, evaluating pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.

Daniel Petrylak, MD, discusses...

03/10/2023

Oncology

Neeraj Agarwal, MD, Huntsman Cancer Institute

Videos

Talazoparib Plus Enzalutamide Improves PFS in Metastatic Castration-Resistant Prostate Cancer

03/08/2023

At the 2023 ASCO Genitourinary Cancers Symposium, Neeraj Agarwal, MD, presented results from a phase 3 trial evaluating enzalutamide plus talazoparib vs enzalutamide plus placebo for patients with metastatic castration-resistant prostate...

At the 2023 ASCO Genitourinary...

03/08/2023

Oncology

Nicholas Van As, MMBCh, Royal Marsden Hospital

Videos

Quality of Life Outcomes: SBRT vs Surgery for Patients with Localized Prostate Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, Nicholas Van As, MMBCh, discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs SBRT with localized prostate cancer.

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology